Wednesday, 15 April 2015

Raw Material Diversification is Latest Buzzword in South Korean Petrochemical Industry


In South Korea, petrochemical companies that have conventionally relied on oil as an energy source are now increasingly moving away from this business structure to explore non-oil based chemicals businesses. As part of this alteration to their business approach, petrochemical companies are investing in additional facilities that are not entirely dependent on oil. This group now includes shale gas, natural gas, liquefied petroleum gas, and condensate obtained through naphtha-based plants. While a departure from traditional oil-based chemicals is a more sustainable business model, the high costs may prove to be a deterrent. Despite that, it is increasingly becoming evident that more and more businesses are opting for this novel business model.

According to a recent report in the country’s leading business portal, Business Korea, market players are expecting their facilities based on unconventional energy sources to reach completion in the immediate future. Hyosung, for one, was expected to extend its Ulsan-based polypropylene plant by the third quarter of the year so as to enhance its polypropylene production capacity to about 500,000 tons per year. 

On similar lines, Lotte Chemicals will be venturing into Uzbekistan by investing in chemical plants that use gas as an energy source. Thus far, the company has pumped in about US$ 338 million in the project, which will also see the Uzbek government participating. This chemical plant is expected to reach completion by the end of 2015. Other companies investing in similar ventures include: Samsung Total, SK Incheon Petrochem, LG Chem and SK Gas.

With this strategy that entails the diversification of raw materials, petrochemical companies in South Korea are hoping to trounce other competitive disadvantages when compared with other oil-producing companies in the Middle East.

Monday, 13 April 2015

Google Joins Superlative-Battery-Development Bandwagon in Backdrop of its Expanding Consumer Electronics and Hardware Businesses

Internet search giant Google has now joined many other leading market players in the quest for batteries that promise superlative performance. The company, which is firmly foraying into the consumer electronics and specialized hardware section, has a comprehensive program for developing better batteries. 

In fact, the company had already begun taking steps in this direction way back in 2012, when it appointed a specialized team headed by Ramesh Bhardwaj, a battery expert who was earlier with Apple. The team primarily worked on testing batteries manufactured by other companies and the compatibility of these batteries with Google’s own devices. However, about a year down the line, the company decided that it was it was perhaps time to develop its own battery technologies.

The group that is currently working on developing batteries for Google is a small one (four members), and works under the aegis of the Google X research lab. 

In recent years, Google has gradually expanded its footprint in industries such as robotics, transportation, communications, healthcare, and so on through physical devices that need efficient batteries to run successfully. In 2013, Google’s chief executive Larry Page had told analysts that there was a pressing need to develop batteries with a long life for mobile devices. This, according to Page, is where a massive potential lies when it comes to offering better experiences to consumers.

Bhardwaj, during previous interactions with industry executives, had said that Google was currently running at least 20 projects that need superior battery technology. The most prominent among these are Google’s self-driving cars that run on rechargeable batteries. 

In fact, analysts observe that Google has also learnt from its failures, when in the past, its first version of Google Glass was plagued with short battery life. The company is now working on improving the same.

Indian Dairy Leader Amul’s Growth Registers Eight-Year Low in Fiscal 2014-15 due to Tumbling Milk Prices


Indian dairy giant Amul’s growth in 2014-15 has been the slowest in the past eight years. The slide in milk prices globally has dented Amul’s revenue growth rate to a marked degree. The company is the foremost dairy brand in India and leads the bulk dairy commodities market, which includes whole and skimmed milk powder and ghee (clarified butter).

The fiscal of the Gujarat Cooperative Milk Marketing Federation came to a close with revenues to the tune of INR 20,730 crores, which marks a 14.2% increase over the year earlier. The company reported a CAGR of 20% in the last five years, in marketing Amul as the leading dairy brand in India. According to the MD of Amul, R.S. Sodhi, the company has achieved its targeted growth in volume sales across all categories of products. 

The company’s range of consumer products has expanded by an impressive 21%, he said. This growth has been especially evident in the ice-cream, beverages and powdered milk pouches segments. Speaking to The Economic Times, a leading Indian business daily, Sodhi said that the company’s bulk commodity sales had shown a drop of 77%. The stakes in Amul group are owned by approximately 32 lakh farmers, operating across 17 milk co-operatives in various Indian districts. The total turnover of the company approximated INR 29,000 crore the company’s MD said.

The dairy, which is based on a co-operative business model, processes a whopping 154 lakh liters of milk, which it procures from a number of states, including Gujarat. The news report further stated that the company was mulling an expansion of plant capacity by a further 14% so it can process at least 175 lakh liters of milk every day.

The company’s growth strategies in the coming years will be centered on the SAARC region and the Middle East.

Thursday, 9 April 2015

Recruitment Process Outsourcing (RPO) Market Expected to Reach US$ 154.7 Mn in 2020: Transparency Market Research

According to a new market report published by Transparency Market Research “Recruitment Process Outsourcing Market - Southeast Asia Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020”, the market was valued at US$ 45.6 Mn in 2013 and is expected to reach US$ 154.7 Mn by 2020, growing at a CAGR of 19.3% from 2014 to 2020. Rest of Southeast Asia (RoSEA) region was the largest contributor to the Southeast Asia recruitment process outsourcing (RPO) market in 2013. However, Indonesia is predicted to be the fastest growing market for RPO solutions during the forecast period, growing at a CAGR of 19.9% from 2014 to 2020. The demand for RPO solutions in Indonesia is majorly driven by the high growth in industrial sectors such as manufacturing, healthcare and pharmaceuticals and others. Another significant factor boosting the demand for RPO solutions is the rapidly rising IT and IT enabled services (ITeS) industries in the nation.

Recruitment process outsourcing (RPO) is outsourcing of a part or entire recruitment process to an RPO provider. The demand for RPO solutions is chiefly driven by the cost reduction advantage of these solutions. Outsourcing RPO solutions to an external service provider enables the organizations to eliminate the burden of recruitment processes and focus on their core competencies. In addition, the RPO providers have advanced tools and technologies required for recruitment processes that ensures quality recruitment results for the client organizations. RPO providers also assume the responsibility of hired candidates. Thus, if any hired candidate leaves the organization in a given period of time, the RPO companies provide free replacement for the candidate. Another significant factor fueling the growth of RPO market in Southeast Asia is high economic growth in the region. Growing industrialization creates large demand for skilled employees in any nation. With rising industrialization in the region, the demand for RPO solutions is expected to soar substantially during the forecast period.

Browse the full Recruitment Process Outsourcing (RPO) Market:
 http://www.transparencymarketresearch.com/south-east-asia-rpo-market.html

The market for recruitment process outsourcing (RPO) in Southeast Asia is segmented on the basis of engagement type, end-use industries and geographic regions. On the basis of engagement type, the RPO market in Southeast Asia is segmented into on-demand RPO and end-to-end RPO. In 2013, the on-demand RPO engagement type accounted for a market share of around 81% of the total RPO market in Southeast Asia. On-demand RPO solutions include outsourcing some part of the recruitment processes and are the more cost effective as compared to end-to-end RPO solutions. This is the most significant factor fueling the demand for these solutions in the region. The on-demand RPO segment is expected to grow at a CAGR of 19.3% from 2014 to 2020 in Southeast Asia RPO market.

On the basis of end-use industries, the Southeast Asia recruitment process outsourcing (RPO) market is segmented into banks financial services and insurance (BFSI); IT, IT enabled services (ITeS) and telecommunication; manufacturing; healthcare and pharmaceuticals; hospitality and others. Others segment comprises aerospace, marine and construction industries. In 2013, IT, ITeS and telecommunication segment accounted for the largest share of around 48.0%, in terms of revenue, of the Southeast Asia recruitment process outsourcing (RPO) market. This was majorly due to the high demand for recruitment in these industries. IT, ITeS and telecommunication segment is expected to remain the largest segment growing at the highest CAGR of 19.6% from 2014 to 2020.

Browse the full Press Release of Recruitment Process Outsourcing (RPO) Market: http://www.transparencymarketresearch.com/pressrelease/south-east-asia-rpo-market.htm

In 2013, Rest of Southeast Asia (RoSEA) led the Southeast Asia recruitment process outsourcing (RPO) market with the market share of around 78% of the Southeast Asia market. Countries such as Singapore and Malaysia are among the early adopters of RPO solutions in the region. In addition, the demand for RPO solutions is driven by rising industrialization in countries such as Myanmar and Philippines. The recruitment process outsourcing (RPO) market in RoSEA is predicted to grow at a CAGR of 19.2% from 2014 to 2020.

The Southeast Asia recruitment process outsourcing (RPO) market includes RPO providers such as Kenexa Corporation (an IBM Corporation Company), Randstad Holding Company, Accolo, Inc., Atterro Human Capital Group, Kelly Outsourcing and Consulting Group, Cielo, Inc. (Pinstripe, Inc.), ManpowerGroup Solutions, Pontoon Solutions, Zyoin Web Pvt. Ltd., Futurestep (a Korn Ferry Company), TalentFusion, Inc., Alexander Mann Solutions and Hudson Global, Inc.

The report studies the Southeast Asia recruitment process outsourcing (RPO) market, and provides estimates in terms of revenue (US$ Mn) from 2010 to 2020. Market estimates are provided on the basis of engagement type, end-use industries and geographic regions. The market has been segmented as follows:

Market Segmentation of Southeast Asia Recruitment Process Outsourcing (RPO) Market:

Recruitment Process Outsourcing (RPO) Market, by Engagement Type
  • On-demand RPO
  • End-to-end RPO
Recruitment Process Outsourcing (RPO) Market, by End-use Industry
  • Banks, Financial Services and Insurance (BFSI)
  • IT, ITeS and Telecommunication
  • Manufacturing
  • Healthcare and Pharmaceuticals
  • Hospitality
  • Others (Aerospace, Marine and Construction Industry)
Recruitment Process Outsourcing (RPO) Market, by Geographic Regions
  • Thailand
  • Indonesia
  • Vietnam
  • Rest of Southeast Asia (RoSEA)

About Us

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Mr. Atil Chaudhari
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

Pulmonary Arterial Hypertension (PAH) Market Expected to Reach USD 5.19 Billion Globally in 2020

According to a new market report published by Transparency Market Research “Pulmonary Arterial Hypertension (PAH) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020,” the global PAH market was valued at USD 4.04 billion in 2013 and is expected to grow at a CAGR of 2.3% from 2014 to 2020, to reach an estimated value of USD 5.19 billion in 2020.

Pulmonary arterial hypertension (PAH) is a medical condition, characterized by restricted blood flow through the pulmonary arteries, which leads to a progressive increase in pulmonary vascular resistance and subsequently right heart failure. PAH is one of the five groups of pulmonary hypertension, classified by the World Health Organization (WHO). PAH occurs, when the pulmonary arteries become narrowed, thickened, or blocked. The advanced therapy to treat PAH includes prostacyclin and prostacyclin analogs, endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5) inhibitors, and soluble guanylate cyclase (sGC) stimulators. This advanced therapy is directed towards PAH itself, and not at the underlying cause of PAH. In addition to the aforementioned classes of drugs, physicians also prescribe drugs such as calcium channel blockers, diuretics, digoxin and anticoagulants to patients with PAH.

Browse the full Pulmonary Arterial Hypertension (PAH) Market: http://www.transparencymarketresearch.com/pulmonary-arterial-hypertension-therapeutics.html

Based on the commercially-available drug classes, to treat PAH, the global PAH market has been segmented into prostacyclin and prostacyclin analogs, endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5) inhibitors, and soluble guanylate cyclase (sGC) stimulators. Prostacyclin and prostacyclin analogs were the first medications approved by the U.S. FDA for the treatment of PAH. Currently, epoprostenol (Flolan and Veletri), treprostinil (Remodulin, Tyvaso and Orenitram), and iloprost (Ventavis) are the three drugs under this category, which are widely used to treat patients with PAH. A new drug called Uptravi (selexipag), which is a selective IP prostacyclin receptor agonist, is expected to be launched in 2016. This new drug is likely to drive growth of the prostacyclin and prostacyclin analogs market during the forecast period from 2014 to 2020.

Endothelin receptor antagonists (ERAs) that inhibit the interaction between endothelin and endothelin receptors have emerged as one of the mainstays in the treatment of PAH. Tracleer (bosentan) is the first U.S. FDA approved ERA that is being used to treat PAH. Letairis/Volibris (ambrisentan) and Opsumit (macitentan) are the other approved ERAs for treating PAH. Of these, Opsumit was approved by the U.S. FDA and the European Commission in December 2013. Opsumit is expected to emerge as the most selling PAH drug by the end of 2020. Tracleer is set to go off-patent in the U.S. and Europe in 2015 and 2017, respectively. Patent expiry of Tracleer is likely to cause a huge set back in growth of the ERAs market during the forecast period from 2014 to 2020.

Revatio (sildenafil) from Pfizer, Inc. and Adcirca (tadalafil) from Eli Lilly/United Therapeutics Corporation are the two U.S. FDA approved PDE-5 inhibitors that are used to treat PAH. Adempas (riociguat) is the only approved sGC stimulator for the treatment of PAH. Adempas is designed to treat PAH by stimulating the nitric oxide receptor sGC, which induces vasodilation. Adempas was first approved by the U.S. FDA in October 2013. During the forecast period between 2014 and 2020, riociguat would face stiff competition from drugs such as macitentan and treprostinil (extended release tablet), as they all are meant for oral administration. The novel mode of action of riociguat would also play a key role in driving growth of this segment during the forecast period.

Browse the full Press Release: http://www.transparencymarketresearch.com/pressrelease/pulmonary-arterial-hypertension-therapeutics-market.htm

The global pulmonary arterial hypertension (PAH) market was dominated by players such as Actelion Pharmaceuticals, Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc, Pfizer, Inc., and United Therapeutics Corporation in 2013. Actelion Pharmaceuticals, Ltd. accounted for the largest share of the overall PAH market in 2013, as one of its products, Tracleer (bosentan), was the bestselling PAH drug in 2013. During the forecast period from 2014 to 2020, Bayer HealthCare, which recently launched a new drug Adempas (riociguat), is likely to witness substantial growth in the PAH space. Arena Pharmaceuticals, Inc., Dong-A ST Co., Ltd., Reata Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Novartis International AG, and Aires Pharmaceuticals, Inc. are some major companies with PAH drugs in their clinical pipeline.

The global PAH market is segmented as follows:

Global Pulmonary Arterial Hypertension Market, by Drug Class
  • Prostacyclin and Prostacyclin Analogs
  • Endothelin Receptor Antagonists (ERAs)
  • Phosphodiesterase-5 (PDE-5) Inhibitors
  • Soluble Guanylate Cyclase (sGC) Stimulators
Pipeline Analysis: Pulmonary Arterial Hypertension Market
  • Early-stage Drug Candidates (Phase I & Phase II)
  • Late-stage Drug Candidates (Phase III & Registration Phase)
Global Pulmonary Arterial Hypertension Market, by Geography
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World (RoW)

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us

Mr. Nachiket
State Tower,
90 State Street, Suite 700,
Albany NY - 12207
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

Asia Pacific Pet Food Market is Expected to Reach USD 10,720.0 Million in 2020: Transparency Market Research

According to a new market report published by Transparency Market Research “Pet Food Market - Asia Pacific Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020,” the asia Pacific pet food market was valued at USD 9,100.0 million in 2013 which is expected to reach USD 10,720.0 million by 2020, growing at a CAGR of 2.3% from 2014 to 2020. In terms of volume the pet food market in Asia Pacific was valued at 688.6 kg million in 2013 and is expected to reach 803.3 kg million by 2020, growing at a CAGR of 2.1% from 2014 to 2020.

The pet food market in terms of pet type has been segmented into dog food, cat food and others. The dog food segment held the largest market share in the pet food market in Asia Pacific. Increasing disposable income and rising trend for nuclear family are some of the major factors fueling the demand for dog food in Asia Pacific. However, the others segment including fish food, reptile food, bird food and other small animals is one of the fastest growing segments in Asia Pacific.


In addition, the pet food market can be further segmented in terms of food type into: dry food, wet food/canned food, nutritious food, snacks/treats and others. The dry food segment held the largest market share in Asia Pacific. Ease of handling and lower prices of dry food as compared to other food types is one of the major factors fueling the demand for dry food in Asia Pacific. However, the nutritious food segment is the fastest growing segment in Asia Pacific. Increasing awareness about pet health is one of the major factors fueling the demand for nutritious food.

The Asia Pacific pet food market is further segmented by country into China, India, Japan, Australia, South Korea and rest of Asia Pacific. Japan is one of the major markets for pet food in Asia Pacific. Increasing trend for nuclear family and demand for small pets is one of the major factors fueling the demand for pet food in Japan. However, with smaller dwelling places the pet food market in Japan is expected to experience stable growth throughout the forecast period.


However, India is the fastest growing market for pet food in Asia Pacific. Increasing demand for companionship and awareness about pet health are some of the major factors fueling the demand for pet food in India. In addition, China is having huge potential for pet food owing to increasing number of pets. China has largest population of dogs as pets globally. Owing to these factors, there is huge untapped potential in pet food market in China. The average selling price (ASP) of snacks/treats segment was the highest in Asia Pacific followed by nutritious food segment.

The pet food market is dominated mostly by major manufacturers such as Nestle S.A., Mars Inc., Procter & Gamble Co. and Colgate-Palmolive Co. among others. However, the local players are still trying to enter these markets due to brand loyalty of the consumers.

Asia Pacific Pet Food Market: By Pet Type
  • Dog Food
  • Cat Food
  • Others
Asia Pacific Pet Food Market: By Food Type
  • Dry Food
  • Wet Food/Canned Food
  • Nutritious Food
  • Snacks/Treats
  • Others
Asia Pacific Pet Food Market: By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Rest of Asia Pacific
About Us

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Mr. Atil Chaudhari
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Hospira Struggles Further under FDA Scrutiny


One FDA scrutiny after another continues to plague pharmaceutical and medical device manufacturer Hospira. These inquiries continue even after pharma giant Pfizer agreed to buy Hospira in a US$17 billion deal in February 2015. However, the scrutiny of Hospira’s manufacturing facilities by the FDA continues.

The company was summoned yet another time by the regulator relating to alleged discrepancies found in one of its facilities based in Italy. In May 2014, the FDA had zeroed-in on ‘significant’ violations by Hospira in its manufacturing practices pertaining to finished pharmaceuticals. The result of these faulty manufacturing practices, according to the FDA, results in ‘adulterated’ drugs being produced. The company then offered a response to these findings but the FDA remained firm on its stance that the company did not have ‘sufficient’ corrective actions. 

The reported problems with Hospira’s manufacturing facilities and processes have been going on for some time now. In fact, less than a week after the Pfizer-Hospira deal was announced, the latter had to recall over 60 batches of its pain relieving injections in the Singapore and U.S. market. The recall was on account of floating particles that were observed in the glass vials.

In December 2014, the company had to recall multiple batches of one of its many cancer drugs because the FDA found that the drug was not potent enough and that it had elevated levels of impurities. 

Besides, in recent months, the FDA found inconsistencies in the company’s facilities in Australia, India and the United States, which led the regulatory body to issue warning letters to the company.